DE69614390D1 - Antiwachstumwirksame proteine aus oozyten von rana pipiens - Google Patents

Antiwachstumwirksame proteine aus oozyten von rana pipiens

Info

Publication number
DE69614390D1
DE69614390D1 DE69614390T DE69614390T DE69614390D1 DE 69614390 D1 DE69614390 D1 DE 69614390D1 DE 69614390 T DE69614390 T DE 69614390T DE 69614390 T DE69614390 T DE 69614390T DE 69614390 D1 DE69614390 D1 DE 69614390D1
Authority
DE
Germany
Prior art keywords
rana pipiens
extract
subjected
effective proteins
growing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69614390T
Other languages
English (en)
Other versions
DE69614390T2 (de
Inventor
J Ardelt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tamir Biotechnology Inc
Original Assignee
Alfacell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfacell Corp filed Critical Alfacell Corp
Publication of DE69614390D1 publication Critical patent/DE69614390D1/de
Application granted granted Critical
Publication of DE69614390T2 publication Critical patent/DE69614390T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69614390T 1995-06-06 1996-06-03 Antiwachstumwirksame proteine aus oozyten von rana pipiens Expired - Lifetime DE69614390T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/467,955 US5728805A (en) 1988-04-06 1995-06-06 Pharmaceuticals and method for making them
PCT/US1996/008304 WO1996039428A1 (en) 1995-06-06 1996-06-03 Antitumor proteins from rana pipiens oocytes

Publications (2)

Publication Number Publication Date
DE69614390D1 true DE69614390D1 (de) 2001-09-13
DE69614390T2 DE69614390T2 (de) 2001-12-06

Family

ID=23857833

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69614390T Expired - Lifetime DE69614390T2 (de) 1995-06-06 1996-06-03 Antiwachstumwirksame proteine aus oozyten von rana pipiens

Country Status (7)

Country Link
US (1) US5728805A (de)
EP (1) EP0837878B1 (de)
JP (1) JP3779999B2 (de)
AT (1) ATE203997T1 (de)
AU (1) AU5964796A (de)
DE (1) DE69614390T2 (de)
WO (1) WO1996039428A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
HU221407B1 (hu) * 1997-03-28 2002-09-28 Gyula Magvasi Ektodermális eredetû szövetekben fellépõ tumoros burjánzást gátló hatóanyag és készítmény, valamint eljárás elõállításukra
EP0975674B1 (de) 1997-05-02 2005-08-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen
US6869604B1 (en) * 1998-03-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant anti-tumor RNAse
US6239257B1 (en) * 1998-12-30 2001-05-29 Alfacell Corporation Family of proteins belonging to the pancreatic ribonuclease a superfamily
US9919034B2 (en) 2014-03-28 2018-03-20 Tamir Biotechnology, Inc. Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
CA2942706C (en) 2014-03-28 2020-01-14 Tamir Biotechnology, Inc. Rnase for use in treating or preventing viral infections
US9642794B2 (en) 2014-08-18 2017-05-09 Tamir Biotechnology, Inc. Antiviral pharmaceutical for topical administration
US10835598B2 (en) 2014-08-18 2020-11-17 Orgenesis Inc. Prophylactic protection against viral infections, particularly HIV
CN107920990A (zh) * 2015-06-15 2018-04-17 塔米尔生物技术公司 用于治疗眼睛的病毒性感染的药物
KR20180058791A (ko) 2015-09-25 2018-06-01 오코겐, 인크. 란피르나제 및/또는 암피나제를 사용하는 바이러스성 결막염의 치료
WO2017142807A1 (en) 2016-02-16 2017-08-24 Tamir Biotechnology, Inc. Treatment or prevention of zika virus infections by administration of a ribonuclease
US11331378B2 (en) 2016-07-26 2022-05-17 Orgenesis Inc. Prophylactic protection against viral infections
ES2881261T3 (es) 2016-07-26 2021-11-29 Luis Squiquera Protección profiláctica contra infecciones virales

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374061A (en) * 1981-07-27 1983-02-15 Center For Blood Research, Inc. Means and methods for purifying Clq, Clr and Cls
US4882421A (en) * 1982-09-23 1989-11-21 Alfacell Corporation Pharmaceutical for treating tumors and method for making it
US5595734A (en) * 1988-04-06 1997-01-21 Alfacell Corporation Compositions comprising ONCONASE (tm) and lovastatin
US5559212A (en) * 1988-04-06 1996-09-24 Alfacell Corporation Frog embryo and egg-derived tumor cell anti-proliferation protein
US5529775A (en) * 1988-04-06 1996-06-25 Alfacell Corporation Compositions comprising ONCONASE(™) and cisplatin, melphalan, or doxorubicin HCl
US5540925A (en) * 1988-04-06 1996-07-30 Alfacell Corporation Compositions comprising ONCONASE (TM) and STELAZINE (TM) or TAMOXIFEN (TM)
EP0500589B1 (de) * 1989-11-13 1994-02-16 Alfacell Corporation Reines protein und bioaktive pharmazeutische produkte
ATE145334T1 (de) * 1992-07-30 1996-12-15 Alfacell Corp Onconase und cisplatin, melphalan und adriamycin enthaltende arzneimittel

Also Published As

Publication number Publication date
ATE203997T1 (de) 2001-08-15
US5728805A (en) 1998-03-17
DE69614390T2 (de) 2001-12-06
EP0837878A1 (de) 1998-04-29
AU5964796A (en) 1996-12-24
JPH11507041A (ja) 1999-06-22
JP3779999B2 (ja) 2006-05-31
EP0837878B1 (de) 2001-08-08
WO1996039428A1 (en) 1996-12-12

Similar Documents

Publication Publication Date Title
DE69614390D1 (de) Antiwachstumwirksame proteine aus oozyten von rana pipiens
Lepage et al. Purification and characterization of the sea urchin embryo hatching enzyme
ATE435661T1 (de) Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
McDevitt et al. Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumors in mice and humans
DE69934967D1 (de) Verfahren zur verminderung der immunogenität von proteinen
FR2792202B1 (fr) Extrait peptidique de lupin et composition pharmaceutique ou cosmetique ou nutraceutique comprenant un tel extrait
DK1032672T3 (da) DNA19355-polypeptid, en tumornekrosefaktor-homolog
WO1999025878A3 (en) Methods for modulating and identifying cellular senescence
ATE246247T1 (de) Varianten des humanen rekombinanten interferon- gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
ATE281528T1 (de) Rekombinante ribonuklease proteine
Sato et al. Proteoglycans of adult bovine compact bone
ATE98869T1 (de) Pharmazeutisches mittel fuer behandlung von menschlichem krebs und verfahren zu seiner herstellung.
ATE218616T1 (de) Humanes zirkulierendes cytokin cc-1
PT1276763E (pt) Proteinas anti-congelantes sua producao e utilizacao
LV10108A (lv) Sunu proliferacijas inhibitori farmaceitiska kompozicija savienojumu iegusanas metode sunu proliferacijas inhibesanas panemieni
IT8723084A0 (it) Impiego di un sistema enzimatico di origine vegetale nell'idrolisi enzimatica di materiale proteico e prodotti cosi' ottenuti.
ES8900018A1 (es) Procedimiento para la fabricacion de derivados aminoalcoholes peptidicos inhibidores de la renina y de las proteasas acidas
ATE374246T1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
GB1174169A (en) Process for the manufacture of preparations rich in interferon
ATE316136T1 (de) Nierenpolycystose-gen
FI961584A0 (fi) C-reaktiivisista proteiinifragmenteista johdetut oligopeptidit
EA200401390A1 (ru) N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения
WO1997014966B1 (en) Method of activating a novel ligand regulatory pathway
DE58907373D1 (de) Modifizierte Proteine.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition